205 related articles for article (PubMed ID: 19882609)
1. Photochromic blockers of voltage-gated potassium channels.
Banghart MR; Mourot A; Fortin DL; Yao JZ; Kramer RH; Trauner D
Angew Chem Int Ed Engl; 2009; 48(48):9097-101. PubMed ID: 19882609
[No Abstract] [Full Text] [Related]
2. Predictive models for hERG potassium channel blockers.
Cianchetta G; Li Y; Kang J; Rampe D; Fravolini A; Cruciani G; Vaz RJ
Bioorg Med Chem Lett; 2005 Aug; 15(15):3637-42. PubMed ID: 15978804
[TBL] [Abstract][Full Text] [Related]
3. Clathrodin, hymenidin and oroidin, and their synthetic analogues as inhibitors of the voltage-gated potassium channels.
Zidar N; Žula A; Tomašič T; Rogers M; Kirby RW; Tytgat J; Peigneur S; Kikelj D; Ilaš J; Mašič LP
Eur J Med Chem; 2017 Oct; 139():232-241. PubMed ID: 28802123
[TBL] [Abstract][Full Text] [Related]
4. Identification of a new class of inhibitors of the voltage-gated potassium channel, Kv1.3, with immunosuppressant properties.
Schmalhofer WA; Bao J; McManus OB; Green B; Matyskiela M; Wunderler D; Bugianesi RM; Felix JP; Hanner M; Linde-Arias AR; Ponte CG; Velasco L; Koo G; Staruch MJ; Miao S; Parsons WH; Rupprecht K; Slaughter RS; Kaczorowski GJ; Garcia ML
Biochemistry; 2002 Jun; 41(24):7781-94. PubMed ID: 12056910
[TBL] [Abstract][Full Text] [Related]
5. Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel.
Beshore DC; Liverton NJ; McIntyre CJ; Claiborne CF; Libby B; Culberson JC; Salata JJ; Regan CP; Lynch JJ; Kiss L; Spencer RH; Kane SA; White RB; Yeh S; Hartman GD; Dinsmore CJ
Bioorg Med Chem Lett; 2010 Apr; 20(8):2493-6. PubMed ID: 20304642
[TBL] [Abstract][Full Text] [Related]
6. Sign Inversion in Photopharmacology: Incorporation of Cyclic Azobenzenes in Photoswitchable Potassium Channel Blockers and Openers.
Trads JB; Hüll K; Matsuura BS; Laprell L; Fehrentz T; Görldt N; Kozek KA; Weaver CD; Klöcker N; Barber DM; Trauner D
Angew Chem Int Ed Engl; 2019 Oct; 58(43):15421-15428. PubMed ID: 31441199
[TBL] [Abstract][Full Text] [Related]
7. Potassium channel block by a tripartite complex of two cationophilic ligands and a potassium ion.
Zimin PI; Garic B; Bodendiek SB; Mahieux C; Wulff H; Zhorov BS
Mol Pharmacol; 2010 Oct; 78(4):588-99. PubMed ID: 20601455
[TBL] [Abstract][Full Text] [Related]
8. Cobatoxin 1 from Centruroides noxius scorpion venom: chemical synthesis, three-dimensional structure in solution, pharmacology and docking on K+ channels.
Jouirou B; Mosbah A; Visan V; Grissmer S; M'Barek S; Fajloun Z; Van Rietschoten J; Devaux C; Rochat H; Lippens G; El Ayeb M; De Waard M; Mabrouk K; Sabatier JM
Biochem J; 2004 Jan; 377(Pt 1):37-49. PubMed ID: 14498829
[TBL] [Abstract][Full Text] [Related]
9. [Influence of 4-aminopyridine on cell proliferation through inhibiting voltage-gated K+ channel in ovarian cancer].
Weng ZP; Wang B; Wang SL; Cui N; Pan XY
Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):762-5. PubMed ID: 17327035
[TBL] [Abstract][Full Text] [Related]
10. Two dyad-free Shaker-type K⁺ channel blockers from scorpion venom.
Zhu L; Gao B; Luo L; Zhu S
Toxicon; 2012 Mar; 59(3):402-7. PubMed ID: 22239942
[TBL] [Abstract][Full Text] [Related]
11. Voltage-gated potassium+ channel expression in coronary artery smooth muscle cells of SHR and WKY.
Hu Z; Ma A; Zhang Y; Xi Y; Fan L; Wang T; Zhang T
Cell Biochem Biophys; 2014 Dec; 70(3):1725-31. PubMed ID: 25030407
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for the inhibition of voltage-dependent K+ channel by gating modifier toxin.
Ozawa S; Kimura T; Nozaki T; Harada H; Shimada I; Osawa M
Sci Rep; 2015 Sep; 5():14226. PubMed ID: 26382304
[TBL] [Abstract][Full Text] [Related]
13. Potent Kv1.3 inhibitors from correolide-modification of the C18 position.
Bao J; Miao S; Kayser F; Kotliar AJ; Baker RK; Doss GA; Felix JP; Bugianesi RM; Slaughter RS; Kaczorowski GJ; Garcia ML; Ha SN; Castonguay L; Koo GC; Shah K; Springer MS; Staruch MJ; Parsons WH; Rupprecht KM
Bioorg Med Chem Lett; 2005 Jan; 15(2):447-51. PubMed ID: 15603971
[TBL] [Abstract][Full Text] [Related]
14. 1,4-Diazabicyclo[2.2.2]octane derivatives: a novel class of voltage-gated potassium channel blockers.
Gordon E; Cohen JL; Engel R; Abbott GW
Mol Pharmacol; 2006 Mar; 69(3):718-26. PubMed ID: 16317109
[TBL] [Abstract][Full Text] [Related]
15. Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5.
Peukert S; Brendel J; Pirard B; Brüggemann A; Below P; Kleemann HW; Hemmerle H; Schmidt W
J Med Chem; 2003 Feb; 46(4):486-98. PubMed ID: 12570371
[TBL] [Abstract][Full Text] [Related]
16. Electrophysiological characterization of a novel Kv channel blocker N,N'-[oxybis(2,1-ethanediyloxy-2,1-ethanediyl) ]bis(4-methyl)-benzenesulfonamide found in virtual screening.
Gao ZB; Chen XQ; Jiang HL; Liu H; Hu GY
Acta Pharmacol Sin; 2008 Apr; 29(4):405-12. PubMed ID: 18358085
[TBL] [Abstract][Full Text] [Related]
17. A bifunctional sea anemone peptide with Kunitz type protease and potassium channel inhibiting properties.
Peigneur S; Billen B; Derua R; Waelkens E; Debaveye S; Béress L; Tytgat J
Biochem Pharmacol; 2011 Jul; 82(1):81-90. PubMed ID: 21477583
[TBL] [Abstract][Full Text] [Related]
18. Bupivacaine inhibits large conductance, voltage- and Ca2+- activated K+ channels in human umbilical artery smooth muscle cells.
Martín P; Enrique N; Palomo AR; Rebolledo A; Milesi V
Channels (Austin); 2012; 6(3):174-80. PubMed ID: 22688134
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of voltage-gated K+ channels and depression of voltage-gated Ca2+ channels are involved in quercetin-induced vasorelaxation in rat coronary artery.
Hou X; Liu Y; Niu L; Cui L; Zhang M
Planta Med; 2014 Apr; 80(6):465-72. PubMed ID: 24710898
[TBL] [Abstract][Full Text] [Related]
20. Discovering potassium channel blockers from synthetic compound database by using structure-based virtual screening in conjunction with electrophysiological assay.
Liu H; Gao ZB; Yao Z; Zheng S; Li Y; Zhu W; Tan X; Luo X; Shen J; Chen K; Hu GY; Jiang H
J Med Chem; 2007 Jan; 50(1):83-93. PubMed ID: 17201412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
